A Phase III Prospective, Multi-center, Randomised, Evaluator-blinded Study to Compare Neuromuscular Junction (NMJ) Targeted Technique for Dysport(R) Injections in Upper Limb Spasticity Post Stroke or Traumatic Brain Injury to the Technique Used in Current Clinical Practice

Trial Profile

A Phase III Prospective, Multi-center, Randomised, Evaluator-blinded Study to Compare Neuromuscular Junction (NMJ) Targeted Technique for Dysport(R) Injections in Upper Limb Spasticity Post Stroke or Traumatic Brain Injury to the Technique Used in Current Clinical Practice

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms NMJ
  • Sponsors Ipsen
  • Most Recent Events

    • 21 Jan 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Sep 2014 Planned number of patients changed from 258 to 272 as reported by ClinicalTrials.gov.
    • 30 Sep 2014 Planned End Date changed from 1 Mar 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top